Received Mar 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
had fever; illness; This non-serious case was reported by a other health professional via sales rep and described the occurrence of fever in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced fever (Verbatim: had fever) and illness (Verbatim: illness). The outcome of the fever and illness were resolved (duration 1 week). It was unknown if the reporter considered the fever and illness to be related to Shingrix. It was unknown if the company considered the fever and illness to be related to Shingrix. Additional Information: GSK Receipt Date: 17-MAR-2025 The other health professional reported that the patient had side effects after dose 1 of Shingrix. The patient had fever and illness for a week.